Multivariate Analysis of Prognostic Factors in Male Breast Cancer in Serbia
Authors:
- Sandra Branko Sipetic-GrujicicSSSandra Branko Sipetic-Grujicic
- Zafir Hajdar MurtezaniZMZafir Hajdar Murtezani
- Zora Borivoje Neskovic-KonstatinovicZNZora Borivoje Neskovic-Konstatinovic
- Jelena Milutin MarinkovicJMJelena Milutin Marinkovic
- Vladimir Nikola KovcinVKVladimir Nikola Kovcin
- Zoran Gojko AndricZAZoran Gojko Andric
- Sanja Vladeta KosticSKSanja Vladeta Kostic
- Isidora Stojan RatkovIRIsidora Stojan Ratkov
- Jadranka Milutin MaksimovicJMJadranka Milutin Maksimovic
Open Access
- 1 April 2014
- journal article
- Published by Asian Pacific Organization for Cancer Prevention in Asian Pacific Journal of Cancer Prevention
- Vol. 15 (7) , 3233-3238
Abstract
Multivariate Analysis of Prognostic Factors in Male Breast Cancer in Serbia Breast cancer;men;survival analysis;predictors; Background: The aim of this study was to analyze the demographic and clinical characteristics of male breast cancer patients in Serbia, and furthermore to determine overall survival and predictive factors for prognosis. Materials and Methods: In the period of 1996-2006 histopathological diagnosis of breast cancer was made in 84 males at the Institute for Oncology and Radiology of Serbia. For statistical analyses the Kaplan-Meier method, long-rank test and Cox proportional hazards regression model were used. Results: The mean age at diagnosis with breast cancer was $64.3{\pm}10.5$ years with a range from 35-84 years. Nearly 80% of the tumors showed ductal histology. About 44% had early tumor stages (I and II) whereas 46.4% and 9.5% of the male exhibitied stages III and IV, respectively. Only 7.1% of male patients were grade one. One-fifth of all patients had tumors measuring ${\leq}2cm$, and 14.3% larger than 5 cm. Lymph node metastasis was recorded in 40.4% patients and 47% relapse. Estrogen and progesterone receptor expression was positive in 66.7% and 58.3%, respectively. Among 14.3% of individuals tumor was HER2 positive. About two-thirds of all male patients had radical mastectomy (66.7%). Adjuvant hormonal (tamoxifene), systematic chemotherapy (CMF or FAC) and adjuvant radiotherapy were given to 59.5%, 35.7% and 29.8% patients respectively. Overall survival rates at five and ten years for male breast cancer were 55.0% and 43.9%, respectively. According to the multivariate Cox regression predictive model, a lower initial disease stage, a lower tumor grade, application of adjuvant hormone therapy and no relapse occurrence were significant independent predictors for good overall survival. Conclusions: Results of the treatment would be better if disease is discovered earlier and therefore health education and screening are an imperative in solving this problem.
Keywords
This publication has 37 references indexed in Scilit:
- Matched-pair analysis of patients with female and male breast cancer: a comparative analysisBMC Cancer, 2011
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011Annals of Oncology, 2011
- Male breast cancerCancer Treatment Reviews, 2010
- Male breast cancerThe Lancet, 2006
- Adjuvant systemic therapy for male breast carcinomaCancer, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Breast carcinoma in menCancer, 2004
- Male breast cancer: a 22-year experienceEuropean Journal of Surgical Oncology, 1998
- Review article: Epidemiology of male breast cancer. A meta‐analysis of published case‐control studies and discussion of selected aetiological factorsInternational Journal of Cancer, 1993
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987